The man who breeds tens of thousands of leeches for the NHS from a tiny Welsh farm Carl Peters-Bond, from Biopharm Leeches in Hendy, is one of just two FDA registered leech farmers in the world Wales Online · Sep 5, 2022
Food expiration dates are confusing A food safety researcher explains another way to know what’s too old to eat Salon · Sep 4, 2022
FDA still skeptical of ALS drug ahead of high-stakes meeting The U.S. Food and Drug Administration has posted another negative review of a closely watched drug for the deadly neurodegenerative disease ALS The Independent UK · Sep 2, 2022
3 Stocks With Decades of Dividend Payments Concerns over high inflation, the Fed’s hawkish stance to control it, and an economic slowdown have led to immense stock market volatility. Therefore, it could be wise to invest in stocks with decades of dividend-paying history, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Becton, Dickinson and Company (BDX),… StockNews.com · Sep 2, 2022
Does Paxlovid cause Covid rebound? US president and first lady have both reported relapses after using drug to treat coronavirus The Independent UK · Sep 2, 2022
EXPLAINER: Should you get a new COVID booster? If so, when? New COVID-19 boosters targeting today’s most common omicron strains should begin arriving within days The Independent UK · Sep 2, 2022
Where Is the Republican Plan To Reform Public Health? The GOP has understandably cast Anthony Fauci as a villain, but there are few plans to overhaul public health bureaucracies. Reason · Sep 2, 2022
"Game-changer" Paxlovid turns into pandemic enigma Paxlovid goes from COVID game-changer to pandemic enigma Axios · Sep 2, 2022
CDC advisers endorse booster shots that target omicron for Americans 12 and up The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday. Los Angeles Times · Sep 1, 2022
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company… Benzinga · Sep 1, 2022
CDC recommends new booster shots to fight omicron CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants. WEKU · Sep 1, 2022
5 Dividend Stocks to Buy and Hold Forever Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to… StockNews.com · Sep 1, 2022
Want to Lower Your Risk? Give These 3 Safe Stocks a Try The uncertainty surrounding the market and the economy because the Federal Reserve signaled to continue hiking interest rates is making investors seek low-risk investments. Given lower volatility and attractive dividend payments, Johnson & Johnson (JNJ), CVS Health (CVS), and Summit Financial Group (SMMF) could be good candidates to consider on… StockNews.com · Sep 1, 2022
Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog. Benzinga · Sep 1, 2022
The Independent UK · Sep 1, 2022 CDC advisers weigh who needs updated COVID booster and when Government advisers are debating who should should get new updated COVID-19 boosters and when
The Conversation · Sep 1, 2022 Will omicron-specific booster shots be more effective at combating COVID-19? 5 questions answered On Sept. 1, 2022, the Centers for Disease Control and Prevention endorsed the use of updated COVID-19 booster shots that are specifically tailored to combat the two most prevalent omicron subvariants, BA.4 and BA.5. The decision comes just a day after the Food and Drug Administration’s emergency use authorization of…
Benzinga · Sep 1, 2022 Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash… Wall Street Journal
Los Angeles Times · Aug 31, 2022 Michael Hiltzik: In blow to public health, judge tosses FDA lawsuit targeting a clinic offering unproven stem cell treatments A federal judge in Riverside, California, declared a stem cell treatment firm operating in the state to be exempt from Food and Drug Administration regulations, opening the door to the further proliferation of clinics offering therapies the FDA says are scientifically unproven and potentially dangerous.
Chicago Sun-Times · Aug 31, 2022 New COVID-19 booster shots could be available in Chicago after Labor Day The FDA today authorized the new booster, which could arrive as early as next week in Chicago, where nearly 2 million residents are expected to be eligible.
Reason · Aug 31, 2022 FDA Approves Updated COVID-19 Booster Shots But does everyone really need to get boosted?
Inverse · Aug 31, 2022 What are the side effects of the new Covid-19 bivalent booster? Last week, the FDA authorized both Pfizer and Moderna's Omicron-specific jabs. Experts say to get them as soon as they are available to you.
Benzinga · Aug 31, 2022 Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
WEKU · Aug 31, 2022 FDA authorizes first revamp of COVID vaccines to target omicron The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.
Benzinga · Aug 31, 2022 MingMed Biotech Joins Queue of Revenue-less Drug Startups Seeking IPO Cash Key Takeaways: With no drug revenues and growing R&D costs, MingMed Biotechnology plans to feed its cash-burning machine with a Hong Kong IPO Company has seven drugs in development, including six in the clinical stages By Ellie Si
The Independent UK · Aug 31, 2022 US clears updated Covid boosters targeting the newest Omicron strain Omicron booster shots could become available within days